Complete financial analysis of Exicure, Inc. (XCUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Exicure, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Epiroc AB (publ) (EPI-A.ST) Income Statement Analysis – Financial Results
- Laster Tech Co., Ltd. (3346.TW) Income Statement Analysis – Financial Results
- Viabuilt Ventures Inc. (VBVT) Income Statement Analysis – Financial Results
- Aplus Biotechnology Corporation Limited (6918.TWO) Income Statement Analysis – Financial Results
- De La Rue plc (DLAR.L) Income Statement Analysis – Financial Results
Exicure, Inc. (XCUR)
About Exicure, Inc.
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 28.83M | -483.00K | 16.61M | 1.30M | 118.00K | 9.72M | 1.04M | 2.39M |
| Cost of Revenue | 1.42M | 1.86M | 1.78M | 32.09M | 19.34M | 14.12M | 13.08M | 13.66M | 10.12M |
| Gross Profit | -1.42M | 26.97M | -2.26M | -15.48M | -18.04M | -14.00M | -3.36M | -12.62M | -7.74M |
| Gross Profit Ratio | 0.00% | 93.56% | 468.32% | -93.19% | -1,392.28% | -11,865.25% | -34.58% | -1,218.44% | -323.95% |
| Research & Development | 1.42M | 19.77M | 48.98M | 32.09M | 19.34M | 14.12M | 13.08M | 13.66M | 10.12M |
| General & Administrative | 12.65M | 10.89M | 13.09M | 9.96M | 8.57M | 7.82M | 7.05M | 3.54M | 5.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -133.00K |
| SG&A | 12.65M | 10.89M | 13.09M | 9.96M | 8.57M | 7.82M | 7.05M | 3.54M | 5.28M |
| Other Expenses | -503.00K | -40.00K | -11.00K | 322.00K | 379.00K | -249.00K | 191.00K | -55.00K | 0.00 |
| Operating Expenses | 13.57M | 30.66M | 62.07M | 42.05M | 27.91M | 21.94M | 20.13M | 17.20M | 15.40M |
| Cost & Expenses | 15.00M | 30.66M | 62.07M | 42.05M | 27.91M | 21.94M | 20.13M | 17.20M | 15.53M |
| Interest Income | 32.00K | 15.00K | 141.00K | 972.00K | 178.00K | 4.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 595.00K | 1.69M | 573.00K | 786.00K | 672.00K | 795.00K | 724.00K | 0.00 |
| Depreciation & Amortization | 1.38M | 1.86M | 1.78M | 1.45M | 724.00K | 358.00K | 232.00K | 180.00K | 133.00K |
| EBITDA | -15.54M | 78.00K | -60.63M | -22.65M | -24.79M | -21.38M | -9.98M | -16.04M | -13.02M |
| EBITDA Ratio | 0.00% | -1.93% | 12,554.87% | -136.61% | -1,954.94% | -18,394.92% | -102.73% | -1,547.97% | -544.85% |
| Operating Income | -15.00M | -1.83M | -62.55M | -25.44M | -26.62M | -21.82M | -10.41M | -16.16M | -13.14M |
| Operating Income Ratio | 0.00% | -6.35% | 12,950.10% | -153.11% | -2,053.78% | -18,490.68% | -107.08% | -1,560.04% | -550.42% |
| Total Other Income/Expenses | -1.92M | -542.00K | -1.55M | 768.00K | 314.00K | -594.00K | -604.00K | -779.00K | -7.00K |
| Income Before Tax | -16.91M | -2.37M | -64.10M | -24.67M | -26.30M | -22.41M | -11.01M | -16.94M | -13.15M |
| Income Before Tax Ratio | 0.00% | -8.23% | 13,271.64% | -148.49% | -2,029.55% | -18,994.07% | -113.29% | -1,635.23% | -550.71% |
| Income Tax Expense | 0.00 | 209.00K | 1.68M | 895.00K | 1.17M | 423.00K | 986.00K | 669.00K | 0.00 |
| Net Income | -16.91M | -2.58M | -64.10M | -24.67M | -26.30M | -22.41M | -11.01M | -16.94M | -13.15M |
| Net Income Ratio | 0.00% | -8.96% | 13,271.64% | -148.49% | -2,029.55% | -18,994.07% | -113.29% | -1,635.23% | -550.71% |
| EPS | -2.11 | -0.56 | -21.70 | -8.49 | -13.68 | -16.32 | -8.37 | -12.93 | -10.04 |
| EPS Diluted | -2.11 | -0.56 | -21.70 | -8.49 | -13.68 | -16.32 | -8.37 | -12.88 | -10.04 |
| Weighted Avg Shares Out | 8.01M | 4.62M | 2.95M | 2.91M | 1.92M | 1.37M | 1.32M | 1.31M | 1.31M |
| Weighted Avg Shares Out (Dil) | 8.01M | 4.62M | 2.95M | 2.91M | 1.92M | 1.37M | 1.32M | 1.32M | 1.31M |
Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer
Exicure, Inc. (XCUR) Reports Q4 Loss, Misses Revenue Estimates
Exicure, Inc. (XCUR) delivered earnings and revenue surprises of -50.00% and -95.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients With Glioblastoma at Northwestern University
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Spherical Nucleic Acid technology shows promising results in phase 0 trial in patients with glioblastoma at Northwestern University.
Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure reported fourth quarter and full year financial results for the year ended December 31, 2020 and provided an update on corporate progress.
Exicure Announces Appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to Its Board of Directors
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.
Exicure, Inc. (XCUR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Exicure, Inc. (XCUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exicure Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021.
Exicure Announces Webcast of Presentation at 2021 HC Wainwright BIOCONNECT Conference
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that David Giljohann, CEO, will present at the HC Wainwright Virtual BIOCONNECT Conference, January 11-14, 2021.
Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc., (NASDAQ:XCUR) a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Exicure, Inc. have entered into a global collaboration...
Source: https://incomestatements.info
Category: Stock Reports
What are Exicure’s Q2 2024 financial highlights?
Exicure’s net loss narrowed to $0.6 million in Q2 2024, compared to $5.8 million in Q2 2023, primarily due to reduced operations and cost-cutting measures. General and administrative expenses decreased significantly to $1.2 million, down from $5.6 million in the same quarter last year.
What is Exicure’s current cash position as of Q2 2024?
Reports Second Quarter 2024 Financial Results. Exicure, Inc. (Nasdaq: XCUR) reported its Q2 2024 financial results, revealing a challenging financial position. The company’s cash and cash equivalents decreased to $0.5 million as of June 30, 2024, from $0.8 million at the end of 2023.